1. DIGITAL.CSIC
  2. Biología y Biomedicina
  3. Instituto de Biología Molecular y Celular del Cáncer de Salamanca (IBMCC)
  4. (IBMCC) Artículos
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/62914
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE

Comparte tu historia
de Acceso Abierto
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Campo DC Valor Lengua/Idioma
dc.contributor.authorRawstron, Andy C.-
dc.contributor.authorOrfao, Alberto-
dc.contributor.authorMateo, Gema-
dc.contributor.authorPérez-Andrés, Martin-
dc.contributor.authorSan Miguel, Jesús F.-
dc.date.accessioned2012-12-14T09:49:27Z-
dc.date.available2012-12-14T09:49:27Z-
dc.date.issued2008-
dc.identifierdoi: 10.3324/haematol.11080-
dc.identifierissn: 0390-6078-
dc.identifiere-issn: 1592-8721-
dc.identifier.citationHaematologica 93(3): 431-438 (2008)-
dc.identifier.urihttp://hdl.handle.net/10261/62914-
dc.descriptionThis is an open access paper.-- et al.-
dc.description.abstractThe European Myeloma Network (EMN) organized two flow cytometry workshops. The first aimed to identify specific indications for flow cytometry in patients with monoclonal gammopathies, and consensus technical approaches through a questionnaire-based review of current practice in participating laboratories. The second aimed to resolve outstanding technical issues and develop a consensus approach to analysis of plasma cells. The primary clinical applications identified were: differential diagnosis of neoplastic plasma cell disorders from reactive plasmacytosis; identifying risk of progression in patients with MGUS and detecting minimal residual disease. A range of technical recommendations were identified, including: 1) CD38, CD138 and CD45 should all be included in at least one tube for plasma cell identification and enumeration. The primary gate should be based on CD38 vs. CD138 expression; 2) after treatment, clonality assessment is only likely to be informative when combined with immunophenotype to detect abnormal cells. Flow cytometry is suitable for demonstrating a stringent complete remission; 3) for detection of abnormal plasma cells, a minimal panel should include CD19 and CD56. A preferred panel would also include CD20, CD117, CD28 and CD27; 4) discrepancies between the percentage of plasma cells detected by flow cytometry and morphology are primarily related to sample quality and it is, therefore, important to determine that marrow elements are present in follow-up samples, particularly normal plasma cells in MRD negative cases.-
dc.description.sponsorshipThe meetings were sponsored by the European Myeloma.-
dc.language.isoeng-
dc.publisherFerrata Storti Foundation-
dc.rightsopenAccess-
dc.titleReport of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders-
dc.typeartículo-
dc.identifier.doi10.3324/haematol.11080-
dc.date.updated2012-12-14T09:49:27Z-
dc.description.versionPeer Reviewed-
dc.identifier.pmid18268286-
dc.type.coarhttp://purl.org/coar/resource_type/c_6501es_ES
item.fulltextWith Fulltext-
item.grantfulltextopen-
item.languageiso639-1en-
item.cerifentitytypePublications-
item.openairetypeartículo-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
Aparece en las colecciones: (IBMCC) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato
Report of the European.pdf192,29 kBAdobe PDFVista previa
Visualizar/Abrir
Show simple item record

CORE Recommender

PubMed Central
Citations

145
checked on 21-abr-2024

SCOPUSTM   
Citations

413
checked on 23-abr-2024

WEB OF SCIENCETM
Citations

352
checked on 29-feb-2024

Page view(s)

542
checked on 24-abr-2024

Download(s)

576
checked on 24-abr-2024

Google ScholarTM

Check

Altmetric

Altmetric


Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.